Colorado

Who we are

  • February 5, 2024
    ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
  • January 17, 2024
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
  • January 10, 2024
    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
  • January 9, 2024
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
  • January 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • August 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • July 24, 2023
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
  • February 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • December 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • July 26, 2022
    GCC19CART for Patients With Metastatic Colorectal Cancer